Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Return on Capital Employed for 15 consecutive years, with 0.26% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 90.0% year-over-year to 0.26%, compared with a TTM value of 0.26% through Dec 2025, up 90.0%, and an annual FY2025 reading of 0.09%, up 80.0% over the prior year.
  • Return on Capital Employed was 0.26% for Q4 2025 at Arrowhead Pharmaceuticals, up from 0.08% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.26% in Q4 2025 and bottomed at 0.66% in Q3 2024.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.25% recorded in 2021.
  • The sharpest move saw Return on Capital Employed plummeted -36bps in 2024, then surged 90bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.35% in 2021, then surged by 33bps to 0.23% in 2022, then tumbled by -102bps to 0.47% in 2023, then crashed by -34bps to 0.64% in 2024, then skyrocketed by 141bps to 0.26% in 2025.
  • Business Quant data shows Return on Capital Employed for ARWR at 0.26% in Q4 2025, 0.08% in Q3 2025, and 0.08% in Q2 2025.